Citations (5)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Shiruyeh Schokrpur, Van Hilburn, Nicholas Giustini & Lyudmila Bazhenova. (2021) An overview of alectinib hydrochloride as a treatment option for ALK positive non-small cell lung cancer. Expert Opinion on Pharmacotherapy 22:14, pages 1815-1824.
Read now
Read now
Huamao M. Lin, Xiaoyun Pan, Peijie Hou, Hui Huang, Yanyu Wu, Kaili Ren & Mohammad Jahanzeb. (2020) Economic burden in patients with ALK + non-small cell lung cancer, with or without brain metastases, receiving second-line anaplastic lymphoma kinase (ALK) inhibitors. Journal of Medical Economics 23:8, pages 894-901.
Read now
Read now
Articles from other publishers (3)
Diego Kauffmann-Guerrero, Kathrin Kahnert & Rudolf M. Huber. (2020) Treatment Sequencing for Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer. Drugs 81:1, pages 87-100.
Crossref
Crossref
Huamao M Lin, Xiaoyun Pan, Peijie Hou, Susan Allen, Pia Baumann & Maximilian J Hochmair. (2020) Real-world treatment duration in ALK-positive non-small-cell lung cancer patients receiving brigatinib through the early access program. Future Oncology 16:15, pages 1031-1041.
Crossref
Crossref
Pascale Tomasini, Julie Egea, Maxime Souquet-Bressand, Laurent Greillier & Fabrice Barlesi. (2019) Alectinib in the treatment of ALK-positive metastatic non-small cell lung cancer: clinical trial evidence and experience with a focus on brain metastases. Therapeutic Advances in Respiratory Disease 13, pages 175346661983190.
Crossref
Crossref